yingweiwo

Imatinib (STI571; Gleevec; Glivec)

Alias: CGP-57148B; ST-1571, CGP057148B; CGP 57148; CGP57148; CGP-57148; CGP57148B; CGP 57148B; STI571; STI 571; Imatinib; US brand name: Gleevec; Foreign brand name: Glivec
Cat No.:V0573 Purity: ≥98%
Imatinib (formerly STI-571, trade name Gleevec and Glivec) is an orally bioavailable multi-targeted kinase inhibitor with potential anticancer activity.
Imatinib (STI571; Gleevec; Glivec)
Imatinib (STI571; Gleevec; Glivec) Chemical Structure CAS No.: 152459-95-5
Product category: PDGFR
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
100mg
250mg
500mg
1g
2g
5g
10g
Other Sizes

Other Forms of Imatinib (STI571; Gleevec; Glivec):

  • Imatinib D8
  • Imatinib D4
  • Imatinib-d3 hydrochloride (STI571-d3 (hydrochloride); CGP-57148B-d3 (hydrochloride))
  • Imatinib Mesylate (STI571; Gleevec; Glivec)
  • Imatinib metabolite N-Desmethyl Imatinib
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: ≥98%

Product Description

Imatinib (formerly STI-571, trade name Gleevec and Glivec) is an orally bioavailable multi-targeted kinase inhibitor with potential anticancer activity. With IC50 values of 0.6 μM, 0.1 μM, and 0.1 μM in cell-free and/or cell-based assays, respectively, it inhibits v-Abl, c-Kit, and PDGFR. In order to inhibit ATP binding, phosphorylation, and the subsequent activation of growth receptors and their downstream signal transduction pathways, imatinib binds to the intracellular domain of tyrosine kinases (TK). Tyrosine kinases carried by the bcr-abl oncogene, along with receptor TKs carried by the c-kit and platelet-derived growth factor receptor (PDGFR) oncogenes, are inhibited by imatinib.

Biological Activity I Assay Protocols (From Reference)
Targets
PDGFR (IC50 = 100 nM); c-Kit (IC50 = 100 nM); v-Abl (IC50 = 600 nM)
ln Vitro
Imatinib (STI571) inhibits c-Kit autophosphorylation, MAPK activation, and Akt activation without changing the overall amounts of c-kit, MAPK, or Akt proteins. Approximately 100 nM is the concentration at which these effects are 50% inhibited[1].
Imatinib (STI571) has a very high in vitro IC50 of 25 nM against the kinase Bcr-Abl, which causes chronic myeloid leukemia. Additionally, Kit (in vitro IC50: 410 nM) and PDGFR (in vitro IC50: 380 nM) are effectively inhibited by imatinib[2].
Imatinib (STI571) is a multi-target inhibitor of v-Abl, c-Kit, and it also inhibits the native PDGFβ receptor, Bcr/Abl, v-Abl, Tel/Abl, and c-Kit. However, it does not inhibit the EGFR, c-Fms, Flt3, Src family kinases, or numerous other tyrosine kinases. Imatinib has no effect on untransformed Ba/F3 cells growing in IL-3 or on Ba/F3 cells transformed by Tel/JAK2[4]. However, it inhibits the tyrosine phosphorylation and cell growth of Ba/F3 cells expressing Bcr/Abl, Tel/Abl, Tel/PDGFβR, and Tel/Arg with an IC50 of approximately 0.5 μM in each case.
Imatinib (STI571), a multi-target inhibitor, has IC50s of 32.4 and 32.8 μM for v-Abl, c-Kit, and BON-1 and H727 cells after 48 hours of exposure[6].
ln Vivo
Tumor growth inhibition is 59.437% in the phosphorothioate antisense oligodeoxynucleotides (PS-ASODN) group, significantly higher than in the liposome negative control group (2.759%) and the Imatinib (STI571) multi-target inhibitor of v-Abl, c-Kit and group (11.071%) groups. When compared to the Imatinib group (1.838±0.241), liposome negative control group (2.013±0.273), and saline group (2.004±0.163), telomerase activity is significantly lower (P<0.01) in the PS-ASODN group (0.689±0.158)[7]. Imatinib (25 mg/kg/day, p.o.) inhibits the growth of endometriotic tissue and decreases the quantity of ovarian follicles in a rat model. Through its inhibitory effects on angiogenesis and cell proliferation, imatinib effectively treats experimental endometriosis[8].
Enzyme Assay
Rabbit antiserum is used to immunoprecipitate the PDGF receptor from extracts of BALB/c 3T3 cells, which is then left on ice for two hours. Antigen-antibody complexes are gathered using protein A-Sepharose beads. TNET (50 mM Tris, pH 7.5, 140 mM NaCl, 5 mM EDTA, 1% Triton X-100), TNE (50 mM Tris, pH 7.5, 140 mM EDTA), and kinase buffer (20 mM Tris, pH 7.5, 10 mM MgCl2) are the three solutions used to wash the immunoprecipitates twice. A variety of drug concentrations are added to the reaction mixture after PDGF (50 ng/mL) stimulation for 10 minutes at 4 °C. Incubation with 10 μCi [7-33P]-ATP and l μM ATP for 10 minutes at 4 °C is used to measure PDGF receptor kinase activity. SDS-PAGE is used to separate immune complexes on 7.5% gels.
Cell Assay
In triplicate, BON-1 and NCI-H727 cells are seeded into flat-bottomed 96-well plates, and they are then left to adhere overnight in either RPMI 1640 complete medium or 10% fetal bovine serum-supplemented DMEM. The medium is then changed to either serum-free medium (which serves as a negative control) or serum-free medium that contains serial dilutions of imatinib. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay is used to count the number of metabolically active cells after 48 hours (control cultures do not reach confluence). The absorbance is then measured at 540 nm using a Packard Spectra microplate reader. Inhibition rate = (1 − a / b) × 100% is the formula used to calculate growth inhibition, where a and b represent the absorbance values of the treated and control groups, respectively.
Animal Protocol
Mice: The 40 SCID mice with tumors are split into four groups at random, with 10 mice in each group: the PS-ASODN group (5 μM, intratumor injection once daily, 0.2 mL per mouse), the Imatinib group (0.1 mg/g body weight), the liposome negative control group (0.01 mL/g), and the saline group (0.01 mL/g). From the seventh to the twenty-eighth day following implantation, the mice in each group are given the appropriate treatment by intratumor injection once a day. The mice are killed after 28 days, and an electronic scale and a vernier caliper are used to measure the tumor's weight as well as its longest and shortest diameters. Tumor growth inhibition is computed.
Rats: It uses adult female Wistar-Albino rats weighing between 220 and 240 g. To assess if endometriosis has occurred, the rats have a second laparotomy twenty-one days following the first surgical procedure. Anastrozole (0.004 mg/day, p.o.), Imatinib (25 mg/kg/day), or normal saline (0.1 mL, i.p.) are the three groups of rats that are randomly assigned to receive treatment for 14 days after having visually confirmed endometriotic implants in 24 rats.
ADME/Pharmacokinetics
Absorption, Distribution and Excretion
Imatinib is well absorbed after oral administration with Cmax achieved within 2-4 hours post-dose. Mean absolute bioavailability is 98%. Mean imatinib AUC increases proportionally with increasing doses ranging from 25 mg to 1,000 mg. There is no significant change in the pharmacokinetics of imatinib on repeated dosing, and accumulation is 1.5- to 2.5-fold at a steady state when Gleevec is dosed once daily.
Imatinib elimination is predominately in the feces, mostly as metabolites. Based on the recovery of compound(s) after an oral 14C-labeled dose of imatinib, approximately 81% of the dose was eliminated within 7 days, in feces (68% of dose) and urine (13% of dose). Unchanged imatinib accounted for 25% of the dose (5% urine, 20% feces), the remainder being metabolites.
Population pharmacokinetics in adult CML patients estimated the steady-state volume of distribution of imatinib to be 295.0 ± 62.5 L.At a dose of 340 mg/m2, the volume of distribution of imatinib in pediatric patients was calculated to be 167 ± 84 L.
Typically, clearance of imatinib in a 50-year-old patient weighing 50 kg is expected to be 8 L/h, while for a 50-year-old patient weighing 100 kg the clearance will increase to 14 L/h. The inter-patient variability of 40% in clearance does not warrant initial dose adjustment based on body weight and/or age but indicates the need for close monitoring for treatment-related toxicities.
Metabolism / Metabolites
CYP3A4 is the major enzyme responsible for the metabolism of imatinib. Other cytochrome P450 enzymes, such as CYP1A2, CYP2D6, CYP2C9, and CYP2C19, play a minor role in its metabolism. The main circulating active metabolite in humans is the N-demethylated piperazine derivative, formed predominantly by CYP3A4. It shows in vitro potency similar to the parent imatinib.
Imatinib has known human metabolites that include N-desmethylimatinib.
Biological Half-Life
Following oral administration in healthy volunteers, the elimination half-lives of imatinib and its major active metabolite, the N-desmethyl derivative (CGP74588), are approximately 18 and 40 hours, respectively.
Toxicity/Toxicokinetics
Hepatotoxicity
Imatinib therapy is associated with three forms of acute liver injury: transient and usually asymptomatic elevations in serum enzymes during treatment, clinically apparent acute hepatitis, and reactivation of an underlying chronic hepatitis B.
Elevations in serum aminotransferase levels are common during imatinib therapy, but ALT levels above 5 times the upper limit of the normal range occur in only 2% to 4% of patients treated for 6 months or more. In addition, mild elevations in serum bilirubin can occur. These abnormalities are usually mild, asymptomatic, and resolve despite continuing therapy. Nevertheless, dose adjustment or temporary discontinuation and restarting at a lower dose may be needed and is recommended if levels are markedly elevated (ALT or AST persistently >5 times ULN or bilirubin >3 times ULN).
In addition, imatinib has been linked to rare instances of clinically apparent acute liver injury with jaundice. The time to onset has varied from 6 days to as long as several years after starting treatment, the usual latency being 2 to 6 months (Cases 1 and 2). The pattern of serum enzyme elevations is typically hepatocellular, although cholestatic and mixed forms of hepatitis have also been reported. The injury can be severe and instances of acute liver failure and death have been reported as well as severe hepatitis resulting in a posthepatitic cirrhosis. Immunoallergic features (rash, fever and eosinophilia) are not common, but some patients develop low levels of autoantibodies and instances of chronic hepatitis on long term imatinib have been reported. More importantly, many instances of an apparent clinical response to prednisone therapy have been described. Recurrence of injury is common with reexposure, but concurrent prednisone therapy may blunt or prevent the recurrence of liver injury and, in some instances, has allowed for continued, long term therapy despite a previous bout of clinically apparent liver injury on imatinib.
Finally, there have been several instances of reactivation of chronic hepatitis B during imatinib therapy in patients with inactive hepatitis B or the HBsAg carrier state (Case 3). The clinical presentation is generally with an acute hepatitis like syndrome with marked elevations in serum ALT and minimal changes in alkaline phosphatase levels. Typically, hepatitis B virus (HBV) DNA is present in serum in increasing levels early in the course of reactivation which rapidly falls to pretreatment levels with recovery. Patients may also test positive for IgM antibody to hepatitis B core antigen (IgM anti-HBc). Reactivation of hepatitis B due to imatinib can be severe and fatal instances have been reported.
Likelihood score: B (likely cause of clinically apparent liver injury as well as reactivation of hepatitis B).
Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation
Limited information indicates that maternal doses of imatinib up to 400 mg daily produce low levels of the drug and its active metabolite in milk. Although a few breastfed infants apparently experienced no adverse effects during maternal use of imatinib, no long-term data are available. Until more data are available, imatinib should be used only with careful monitoring during breastfeeding. National Comprehensive Cancer Network guidelines, the manufacturer and some authors recommend that breastfeeding be discontinued during imatinib therapy and for 1 month after therapy.
◉ Effects in Breastfed Infants
A woman receiving oral imatinib 400 mg daily for chronic myeloid leukemia breastfed her infant. No adverse effects were noted in the infant during the first 2 months of nursing.
One woman with chronic myelogenous leukemia received imatinib 400 mg daily throughout pregnancy and during breastfeeding (extent not stated) for nearly 6 months postpartum. Her infant reportedly grew and developed normally.
A woman with chronic myeloid leukemia received imatinib 400 mg daily starting at week 8 of pregnancy and continuing throughout 8 months of breastfeeding (extent not stated). The infant was healthy, but an atrial septal defect was repaired at 30 months of age. It was thought to be unrelated to imatinib therapy.
A pregnant woman with Philadelphia chromosome-positive chronic myelogenous leukemia was started on imatinib 400 mg daily during pregnancy. After delivery, her preterm infant was fed colostrum until the middle of the fifth day postpartum when exclusive formula feeding was instituted. The infant was treated for apnea of prematurity and discharged on day 25 of life. No adverse effects on growth or development were noted during the first year of life.
◉ Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Protein Binding
At clinically relevant concentrations of imatinib, binding to plasma proteins in in vitro experiments is approximately 95%, mostly to albumin and α1-acid glycoprotein.
References

[1]. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000 Aug 1;96(3):925-32.

[2]. Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. Clin Cancer Res. 2007 Jun 1;13(11):3363-9.

[3]. Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract. 2014;2014:357027.

[4]. ARG tyrosine kinase activity is inhibited by STI571.Blood. 2001 Apr 15;97(8):2440-8.

[5]. Coronavirus S Protein-Induced Fusion Is Blocked Prior to Hemifusion by Abl Kinase Inhibitors. J Gen Virol. 2018 May;99(5):619-630.

[6]. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res. 2007 Jan 1;13(1):234-40.

[7]. Depletion of telomerase RNA inhibits growth of gastrointestinal tumors transplanted in mice. World J Gastroenterol. 2013 Apr 21;19(15):2340-7.

[8]. Effect of imatinib on growth of experimental endometriosis in rats. Eur J Obstet Gynecol Reprod Biol. 2016 Feb;197:159-63.

[9]. Frieman MB. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion. J Virol. 2016;90(19):8924‐8933. Published 2016 Sep 12.

Additional Infomation
Pharmacodynamics
Imatinib is a 2-phenylaminopyrimidine derivative neoplastic agent that belongs to the class of tyrosine kinase inhibitors. Although imatinib inhibits a number of tyrosine kinases, it is quite selective toward the BCR-ABL fusion protein that is present in various cancers. BCR-ABL pathway controls many downstream pathways that are heavily implicated in neoplastic growth such as the Ras/MapK pathway (cellular proliferation), Src/Pax/Fak/Rac pathway (cellular motility), and PI/PI3K/AKT/BCL-2 pathway (apoptosis pathway). Therefore, the BCR-ABL pathway is an attractive target for cancer treatment. Although normal cells also depend on these pathways for growth, these cells tend to have redundant tyrosine kinases to continually function in spite of ABL inhibition from imatinib. Cancer cells, on the other hand, can have a dependence on BCR-ABL, thus more heavily impacted by imatinib.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C29H31N7O
Molecular Weight
493.6
Exact Mass
493.259
Elemental Analysis
C, 70.56; H, 6.33; N, 19.86; O, 3.24
CAS #
152459-95-5
Related CAS #
Imatinib-d8;1092942-82-9;Imatinib-d4;1134803-16-9;Imatinib-d3 hydrochloride;1134803-18-1;Imatinib Mesylate;220127-57-1;N-Desmethyl imatinib;404844-02-6
PubChem CID
5291
Appearance
White to off-white to brownish or yellowish tinged crystalline powder
Density
1.3±0.1 g/cm3
Boiling Point
451°C
Melting Point
113°C
Flash Point
196°C
Vapour Pressure
6.03E-24mmHg at 25°C
Index of Refraction
1.672
LogP
2.48
Hydrogen Bond Donor Count
2
Hydrogen Bond Acceptor Count
7
Rotatable Bond Count
7
Heavy Atom Count
37
Complexity
706
Defined Atom Stereocenter Count
0
SMILES
O=C(C1C([H])=C([H])C(=C([H])C=1[H])C([H])([H])N1C([H])([H])C([H])([H])N(C([H])([H])[H])C([H])([H])C1([H])[H])N([H])C1C([H])=C([H])C(C([H])([H])[H])=C(C=1[H])N([H])C1=NC([H])=C([H])C(C2=C([H])N=C([H])C([H])=C2[H])=N1
InChi Key
KTUFNOKKBVMGRW-UHFFFAOYSA-N
InChi Code
InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)
Chemical Name
4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
Synonyms
CGP-57148B; ST-1571, CGP057148B; CGP 57148; CGP57148; CGP-57148; CGP57148B; CGP 57148B; STI571; STI 571; Imatinib; US brand name: Gleevec; Foreign brand name: Glivec
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: ~4 mg/mL (~8.1 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In Vivo)
Solubility in Formulation 1: ≥ 1.25 mg/mL (2.53 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 1.25 mg/mL (2.53 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

View More

Solubility in Formulation 3: ≥ 1.25 mg/mL (2.53 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.


Solubility in Formulation 4: 2% DMSO+30% PEG 300+2% Tween 80+ddH2O: 2mg/mL

Solubility in Formulation 5: 11 mg/mL (22.29 mM) in 0.5% CMC-Na/saline water (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.0259 mL 10.1297 mL 20.2593 mL
5 mM 0.4052 mL 2.0259 mL 4.0519 mL
10 mM 0.2026 mL 1.0130 mL 2.0259 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05493215 Active
Recruiting
Drug: Imatinib Gastrointestinal Stromal Tumors Reema A. Patel November 2023 Phase 2
NCT04138381 Active
Recruiting
Drug: Imatinib
Drug: Selinexor
GIST
Drug Use
Grupo Espanol de Investigacion
en Sarcomas
August 16, 2019 Phase 1
Phase 2
NCT01742299 Active
Recruiting
Drug: imatinib mesylate GIST and CML Novartis Pharmaceuticals March 26, 2013 Phase 4
NCT02413736 Active
Recruiting
Drug: Imatinib Sarcoma Heikki Joensuu May 2015 Phase 3
NCT03193281 Active
Recruiting
Drug: Dasatinib
Drug: Imatinib
Chronic Myeloid Leukemia University of Auckland, New
Zealand
July 17, 2017 Phase 2
Biological Data
  • Imatinib (STI571)

  • Imatinib (STI571)
Contact Us